Article and Video CATEGORIES
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.
Please feel free to offer comments and raise questions in our Discussion Forums.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi and welcome to Grace. Wow, I don't know why you can't get in to see your doc but I'd find a way or find another doc who can walk you...
Hi Amber, Welcome to Grace. I'm so sorry you're going through this scare. It could be a recurrence. It also is as likely to be the contrast creating a better view. ...
Hi Blaze,
As much as I hate to say it, Welcome back Blaze. It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...
Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3
It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...
I had the robotic biopsy but they were unable to reach the spot as they were blocked due to radiation scarring in the Hilar (from treatments in 2000). My pulmonologist took...